Pfizer’s discount to AbbVie is widening the valuation question in pharma’s core medicines

Shares of Pfizer Inc. (NYSE:PFE) have been trading at a discount to AbbVie Inc. (NYSE:ABBV), even as both companies have reported growth in important parts of their pharmaceutical portfolios, according to a Yahoo Finance market comparison published Oct. 16, 2026.

The article frames the debate for investors around a basic valuation question: if both companies are growing key lines of business, why does the market assign Pfizer a lower multiple than AbbVie? The piece does not attempt to settle the dispute, but instead points to the contrast between each firm’s current stock pricing and its operating progress in select therapeutic areas.

In the comparison, the central premise is not that the drug makers are identical, but that they are facing enough overlap in investor attention that the relative gap matters. Pfizer is widely known for a broad portfolio spanning oncology, immunology, and vaccines, while AbbVie is associated with durable cash flow drivers, particularly in immunology and other specialty categories. The Yahoo write-up uses that backdrop to argue that the discount may be meaningful for how investors expect each company’s pipeline and near-term earnings to evolve.

The question, as presented in the Yahoo Finance story, is whether Pfizer’s cheaper valuation reflects deteriorating prospects or simply a different path for future growth. AbbVie’s higher-priced valuation, by contrast, implies investors are more confident about the durability of its earnings streams or the timing and impact of pipeline contributions. Without the detailed figures in the Yahoo post, the underlying drivers of each stock’s relative valuation cannot be confirmed from the information available here.

One way markets often express these disagreements is through how they price drug lifecycles, including expected changes in demand as patents expire, competitive pressures intensify, or new therapies expand. For drug companies, even modest shifts in expectations about product sales trajectories can move valuation metrics quickly. The Yahoo comparison suggests investors are actively debating those expectations when they price the two companies against each other.

Still, the article’s framing is constrained by what it chose to disclose. It emphasizes the broad fact that Pfizer trades at a “considerable” discount to AbbVie and that both companies have posted growth in key parts of their portfolios, but it does not, in the available material, provide a full breakdown of valuation inputs, product-by-product drivers, or how much of the discount may be explained by differences in shareholder returns, balance sheets, or geographic mix.

For investors and analysts, the practical takeaway is not the conclusion that one stock is “right,” but the recognition that the market is indicating uncertainty. Pfizer’s lower valuation implies more skepticism about what comes next, while AbbVie’s premium implies less skepticism or higher expected growth and durability. The gap can persist for long periods, especially in healthcare, where pipeline execution and regulatory outcomes often take years to show up in results.

What to watch next is a clearer reconciliation of portfolio growth with valuation. As each company updates investors through earnings releases and guidance, market participants will likely focus on whether Pfizer’s growth tracks toward the confidence embedded in its pricing and whether AbbVie’s outperformance justifies the premium the market is currently assigning. Until then, the Yahoo comparison leaves open whether the discount is an opportunity, a warning, or simply a reflection of uncertainty that has not yet resolved.